semaglutide miami beach GLP-1 Clinic in Coral Gables and Pinecrest, FL Medical Weight Loss Injections in

9) Mini Case A 55-year-old diabetic patient with high LDL was started on Atorvastatin 20 mg

Retatrutide is still in clinical trials but the retatrutide dosing guide covers available protocol data

Our team is with you at every stage, from the first consultation to continued monitoring and dose modifications

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials